132 related articles for article (PubMed ID: 36175779)
21. Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study.
Goto H; Izutsu K; Ennishi D; Mishima Y; Makita S; Kato K; Hanaya M; Hirano S; Narushima K; Teshima T; Nagai H; Ishizawa K
Int J Hematol; 2022 Dec; 116(6):911-921. PubMed ID: 36107394
[TBL] [Abstract][Full Text] [Related]
22. Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies.
Hatake K; Chou T; Doi T; Terui Y; Kato H; Hirose T; Seo S; Pourdehnad M; Ogaki Y; Fujimoto H; Hagner PR; Yamamoto K
Cancer Sci; 2021 Jan; 112(1):331-338. PubMed ID: 33075165
[TBL] [Abstract][Full Text] [Related]
23. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ogura M; Uchida T; Taniwaki M; Ando K; Watanabe T; Kasai M; Matsumoto Y; Shimizu D; Ogawa Y; Ohmachi K; Yokoyama H; Tobinai K;
Cancer Sci; 2010 Sep; 101(9):2054-8. PubMed ID: 20594195
[TBL] [Abstract][Full Text] [Related]
24. Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
Morcos PN; Moss J; Austin R; Hiemeyer F; Zinzani PL; Beckert V; Mongay Soler L; Childs BH; Garmann D
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1666-1686. PubMed ID: 37389853
[TBL] [Abstract][Full Text] [Related]
25. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
de Vos S; Swinnen LJ; Wang D; Reid E; Fowler N; Cordero J; Dunbar M; Enschede SH; Nolan C; Petrich AM; Ross JA; Salem AH; Verdugo M; Agarwal S; Zhou L; Kozloff M; Nastoupil LJ; Flowers CR
Ann Oncol; 2018 Sep; 29(9):1932-1938. PubMed ID: 30060083
[TBL] [Abstract][Full Text] [Related]
27. Copanlisib: First Global Approval.
Markham A
Drugs; 2017 Dec; 77(18):2057-2062. PubMed ID: 29127587
[TBL] [Abstract][Full Text] [Related]
28. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
29. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
30. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
Panayiotidis P; Follows GA; Mollica L; Nagler A; Özcan M; Santoro A; Stevens D; Trevarthen D; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL; Dreyling M
Blood Adv; 2021 Feb; 5(3):823-828. PubMed ID: 33560394
[TBL] [Abstract][Full Text] [Related]
32. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE; Sehn LH; Matasar M; Schuster SJ; Assouline S; Giri P; Kuruvilla J; Canales M; Dietrich S; Fay K; Ku M; Nastoupil L; Cheah CY; Wei MC; Yin S; Li CC; Huang H; Kwan A; Penuel E; Bartlett NL
Lancet Oncol; 2022 Aug; 23(8):1055-1065. PubMed ID: 35803286
[TBL] [Abstract][Full Text] [Related]
34. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
36. Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study.
Kinoshita T; Hatake K; Yamamoto K; Higuchi Y; Murakami S; Terui Y; Yokoyama M; Maruyama D; Makita S; Hida Y; Saito T; Tobinai K
Jpn J Clin Oncol; 2021 Jan; 51(1):70-77. PubMed ID: 33029633
[TBL] [Abstract][Full Text] [Related]
37. Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
Eltantawy A; Vallejos X; Sebea E; Evans K
Ann Pharmacother; 2019 Sep; 53(9):954-958. PubMed ID: 30813760
[No Abstract] [Full Text] [Related]
38. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
39. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
40. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Tannir NM; Forero-Torres A; Ramchandren R; Pal SK; Ansell SM; Infante JR; de Vos S; Hamlin PA; Kim SK; Whiting NC; Gartner EM; Zhao B; Thompson JA
Invest New Drugs; 2014 Dec; 32(6):1246-57. PubMed ID: 25142258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
